How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

202 results for

Ciclopirox

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A Full Text available with Trip Pro

Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A Eukaryotic translation initiation factor eIF5A has been implicated in HIV-1 replication. This protein contains the apparently unique amino acid hypusine that is formed by the post-translational modification of a lysine residue catalyzed by deoxyhypusine synthase and deoxyhypusine hydroxylase (DOHH). DOHH activity is inhibited by two clinically used drugs (...) , the topical fungicide ciclopirox and the systemic medicinal iron chelator deferiprone. Deferiprone has been reported to inhibit HIV-1 replication in tissue culture.Ciclopirox and deferiprone blocked HIV-1 replication in PBMCs. To examine the underlying mechanisms, we investigated the action of the drugs on eIF5A modification and HIV-1 gene expression in model systems. At early times after drug exposure, both drugs inhibited substrate binding to DOHH and prevented the formation of mature eIF5A. Viral gene

2009 Retrovirology

142. Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus. Full Text available with Trip Pro

Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus. Antifungal effects of iron chelators (lactoferrin, deferoxamine, deferiprone, and ciclopirox) were tested alone and in combination with antifungal drugs against Aspergillus fumigatus B5233 conidia. Lactoferrin, ciclopirox, and deferiprone inhibited whereas deferoxamine enhanced fungal growth. Antifungal synergy against conidia was observed (...) for combinations of ketoconazole with ciclopirox or deferiprone, lactoferrin with amphotericin B, and fluconazole with deferiprone. Iron chelation alone or combined with antifungal drugs may be useful for prevention and treatment of mycosis.

2009 Antimicrobial Agents and Chemotherapy

143. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. (Abstract)

An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. A new 8% ciclopirox-medicated nail lacquer (P-3051), based on a new technology, revealed superior properties in terms of affinity to keratin, nail permeation, and ease of use.This study aims to assess the efficacy and safety of P-3051 vs. the market 8% ciclopirox nail lacquer.This is a multicentre, randomized, three-arm, placebo-controlled, parallel groups, evaluator-blinded (...) ), and those who achieved the endpoint 'decrease of diseased nail' were 40% higher (P < 0.05).Ciclopirox 8% hydrolacquer is more active than reference ciclopirox nail lacquer in the treatment of onychomycosis.

2009 Journal of the European Academy of Dermatology and Venereology : JEADV Controlled trial quality: uncertain

144. Evaluating costs for onychomycosis treatments: a practitioner's perspective

on the reliability of the study and the conclusions drawn. Health technology The study examined several treatments for patients with onychomycosis. Specifically, griseofulvin (GRI), itraconazole (ITRA), fluconazole (FLU), terbinafine (TERB) and 8% ciclopirox lacquer (CICLO). Some combination therapies were also considered. Different dosages and duration of treatment were also considered for each drug under analysis. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population

2006 NHS Economic Evaluation Database.

145. Cost-effectiveness of diagnostic tests for toenail onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests

as symptoms of subungual debris with onycholysis and/or onychauxis). Patients younger than 18 years of age were excluded from the study, as were those with documented psoriasis, lichen planus, or other nail dystrophies. Also excluded were patients on oral antifugal medication for more than 2 months during the 12 months prior to enrolment, and individuals who had used topical ciclopirox nail lacquer within 6 weeks of enrolment. Setting The setting was primary care. The economic study was carried out

2006 NHS Economic Evaluation Database.

146. Pharmacoeconomic analysis of sequential treatment pathways in the treatment of onychomycosis

, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of ciclopirox (CIC) nail lacquer, itraconazole pulse treatment (ITRA pulse), terbinafine (TERB) and itraconazole continuous treatment (ITRA cont) for the treatment of onychomycosis was examined. Recommended regimens were 250 mg/day TERB for 12 to 16 weeks, 200 mg/day ITRA cont for 12 to 16 weeks, 200 mg ITRA pulse twice daily for one week per month (...) ITRA pulse was the first-line agent, the cost of ITRA was the variable with the greatest impact on the model results. Authors' conclusions A treatment pathway for toenail onychomycosis that used ciclopirox (CIC) nail lacquer solution 8% as a first-line agent was a cost-effective strategy from the perspective of the health care system. CRD COMMENTARY - Selection of comparators The authors justified the choice of the comparators, which represented commonly used agents for the treatment

2005 NHS Economic Evaluation Database.

147. Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails

contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Four antifungal agents for the treatment of onychomycosis of the toenails and fingernails were considered. The oral and topical therapies assessed were itraconazole-continuous, itraconazole-pulse, terbinafine and ciclopirox. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study (...) combined using a meta-analysis. Investigation of differences between primary studies The authors reported that consensus about differences between the studies was reached through discussion. Results of the review The success rates were: with itraconazole-continuous, 0.926 for fingernail and 0.645 for toenail; with itraconazole-pulse, 0.793 for fingernail and 0.565 for toenail; with terbinafine, 0.965 for fingernail and 0.811 for toenail; and with ciclopirox, 0.321 for toenail (the success rate

2003 NHS Economic Evaluation Database.

148. Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany

EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of antifungal agents in the treatment of patients with toenail onychomycosis. The agents considered were as follows: (1)itraconazole, continuous regimen, (2) itraconazole, 1-week pulse dosage regimen, (3) oral terbinafine, (4) topical ciclopirox nail varnish. Type of intervention (...) % (+/- 10%); ciclopirox nail varnish, 55.0% (+/- 4%). Methods used to derive estimates of effectiveness Estimates of effectiveness were also based on authors' assumptions. Estimates of effectiveness and key assumptions The efficacy rate of the second line therapy was assumed to be an average of the two most effective antifungal agents (pulsed itraconazole and oral terbinafine). Relapse rates were not included in the analysis because of lack of sufficient data on itraconazole therapies. Measure

1996 NHS Economic Evaluation Database.

149. Is there any evidence of a better cure rate for treating proven fungal toe nail infections with both oral and topical preparations?

therapy can be advocated.” The recent RCT was published in 2005 looked at Ciclopirox topical solution combined with terbinafine to treat onychomycosis [6]. 73 patients were randomised to 1 of 3 treatment arms: ciclopirox nail lacquer once daily for 48 weeks plus 4 weeks of terbinafine 250 mg/day, followed by 4 weeks of rest (no terbinafine), then another 4 weeks of terbinafine 250 mg/day (PLs); ciclopirox nail lacquer once daily for 48 weeks plus terbinafine 250 mg/day for 12 weeks (PL12 (...) Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. Drugs Dermatol. 2005 Jul-Aug;4(4):481-5. ( ) Answered 9 February 2006 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2006 TRIP Answers

150. Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete's Foot)

over group) study period Exclusion Criteria: Has a diagnosis of either psoriasis or eczema Has a visual diagnosis, by the investigator, of onychomycosis. Use of topical antifungals e.g. (clotrimazole, ketoconazole,miconazole, oxiconazole- (Oxistat®, Glaxo Smith Kline), sulconazole, naftifine (Naftin®, Merz), terconazole, econazole nitrate (Spectazole®, Ortho-McNeil), butoconazole ,Fluconazole, ciclopirox olamine-(Loprox®, Medicis), tolnaftate, haloprogin), Zeasorb-AF , antibacterials

2008 Clinical Trials

151. Increased Endogenous Nitric Oxide Release by Iron Chelation and Purinergic Activation in the Rat Carotid Body Full Text available with Trip Pro

by microsensor inserted into the isolated carotid body superfused with bicarbonate-buffer were examined. Suramin did not change the resting NO level under normoxic conditions but it significantly decreased the hypoxia-induced NO elevation in a dose-dependent manner. Suramin (100muM) blocked the NO response to acute hypoxia by 53%. Intracellular iron chelator, ciclopirox olamine (CPX) significantly increased the resting NO release close to the hypoxic level, which was reversed by FeSO(4) or blocked by L-NMMA

2007 The Open Biochemistry Journal

152. Dermacase. Pityriasis rosea. Full Text available with Trip Pro

Dermacase. Pityriasis rosea. 14761101 2004 02 24 2018 11 30 0008-350X 50 2004 Jan Canadian family physician Medecin de famille canadien Can Fam Physician Dermacase. Pityriasis rosea. 41, 49-50 Turchin Irina I Faculty of Medicine, University of Calgary, Alberta. Adams Stewart P SP Enta Tom T eng Case Reports Journal Article Canada Can Fam Physician 0120300 0008-350X 0 Antifungal Agents 0 Pyridones 19W019ZDRJ Ciclopirox IM Acute Disease Adolescent Antifungal Agents therapeutic use Ciclopirox

2004 Canadian Family Physician

153. Fungal toenail infections Full Text available with Trip Pro

of evidence for interventions.In this systematic review we present information relating to the effectiveness and safety of the following interventions: amorolfine, butenafine, ciclopirox, fluconazole, griseofulvin, itraconazole, ketoconazole, mechanical debridement, terbinafine, and tioconazole.

2008 BMJ Clinical Evidence

154. Can the use of a topical antifungal nail lacquer reduce risk for diabetic foot ulceration? Results from a randomised controlled pilot study. (Abstract)

involving daily self-inspection with the possible use of an AFL (ciclopirox 8%) versus self-inspection instructions alone (NAFL). Patients were followed for 12 months or until ulceration. Using an intent to treat analysis, there was no significant difference in proportion of persons ulcerating in the AFL versus the NAFL groups (5.9% versus 5.6% P = 0.9). There was also no difference in the number of unexpected visits (P = 0.2) or missed appointments (P = 0.7) between treatment arms. Interestingly, while

2005 International wound journal Controlled trial quality: uncertain

155. Review of antifungal therapy and the severity index for assessing onychomycosis: Part I. (Abstract)

Review of antifungal therapy and the severity index for assessing onychomycosis: Part I. This review outlines recent data on treatment modalities and outcomes with antifungal therapy in onychomycosis. Included are topical, mechanical, chemical and systemic treatments or a combination thereof. Topical treatments, or transungual drug delivery systems (TUDDS), including ciclopirox and amorolfine were shown to be effective if used alone for mild-moderate nail involvement. Specifically, superficial

2008 Journal of Dermatological Treatment

156. A case report of Hailey-Hailey disease treated with alefacept (Amevive((R))). (Abstract)

ciclopirox, tazarotene cream, pimecrolimus cream and tacrolimus ointment. Partial response of this patient's perineal disease was achieved with Amevive 15 mg weekly for 12 weeks, intramuscularly. To our knowledge, this case represents the first such published report of successful treatment of Hailey-Hailey disease using alefacept.

2007 British Journal of Dermatology

157. Common fungal infections of the feet in patients with diabetes mellitus. (Abstract)

is the least effective agent when compared with the newer agents. Terbinafine, itraconazole and fluconazole have been shown to have acceptable cure rates. More recently, topical treatment of the nail with 8% ciclopirox nail lacquer, bifonazole with urea and amorolfine have been reported to be successful. Over the past decade, fungal foot infections of the skin and nail are more effectively treated with the introduction of numerous topical and oral agents.

2004 Drugs & Aging

158. Onychomycosis in the elderly : drug treatment options. (Abstract)

interactions, and a lower cost than continuous itraconazole therapy. Adjunct debridement may improve the clinical and complete cure rates compared with terbinafine alone. Common adverse effects of terbinafine in the elderly include nausea, sinusitis, arthralgia and hypercholesterolaemia. For onychomycosis caused by Candida or nondermatophyte moulds, there is no superior systemic therapy. In general, topical nail lacquers, amorolfine and ciclopirox are not practical for elderly patients because

2007 Drugs & Aging

159. Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva. (Abstract)

lacked reactive cells.NIH-353 identifies mature eIF5A-1 as an in situ biomarker for proliferation. Like Ki-67, this immunoreagent promises broad applicability in histopathological diagnosis and may be helpful in outcome prediction. In contrast to Ki-67, NIH-353 visualizes a molecular target for antineoplastic therapy, and thus may guide the development and clinical testing of drugs that, like the fungicide ciclopirox, inhibit hypusine formation and cell proliferation.

2004 Gynecologic Oncology

160. Treatment costs of three nail lacquers used in onychomycosis. (Abstract)

Treatment costs of three nail lacquers used in onychomycosis. To assess the daily treatment costs and the average cost-effectiveness of three topical onychomycosis therapies - amorolfine 5% and ciclopirox 8% nail lacquers and tioconazole 28% nail solution - when used as indicated in France, the UK, Germany and Italy.The quantity of drug required and nail size measurements were investigated and, knowing the cost per bottle of each study drug, used to calculate the average treatment cost per (...) patient. Using the prevalence of infection data, the weighted average total treatment cost per patient and hence the weighted average daily treatment cost and cost per patient cured, were calculated.Amorolfine was consistently more cost-effective in terms of weighted average daily treatment cost and cost per patient cured than ciclopirox and tioconazole, when all therapies were used as indicated to treat onychomycosis. In France, for example, the weighted average daily treatment cost of amorolfine

2005 Journal of Dermatological Treatment

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>